Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 22Thoracic 9Endocrine 5Head & Neck 4NET 3Sarcoma 2Gynecologic 2Tumor-Agnostic 1Other solid neoplasm 1Breast 1

Conditions

Neuroendocrine Tumors 2Pulmonary Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × surufatinib × NET × Clear all
NCT07357623 2026-01-22

Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors

Shanghai Chest Hospital

Phase 2 Recruiting
96 enrolled
EndocrineNET

Pulmonary Neuroendocrine Tumor

NCT04579679 2025-07-25

Open-Label Surufatinib in European Patients With NET

Hutchmed

Phase 2 Terminated
78 enrolled 20 charts
EndocrineNET

Neuroendocrine Tumors

NCT05165407 2025-03-14

NESSIE

Peking University

Phase 2 Recruiting
30 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡